1/11 Statins are increasingly linked in both genetic and clinical research to higher rates of insulin resistance and type 2 diabetes - and the mechanism may not be a “side effect” at all, but a direct consequence of how statins 'work'.
/2 2/11 Randomized controlled trials have repeatedly shown increased incidence of T2D in statin users, especially with higher-intensity treatment. Genetic studies examining variants in the HMG-CoA reductase pathway show the same pattern.
/3

1/9 A lot of people dismiss this, but statin-related muscle and tendon damage is well documented.
Statins block the mevalonate pathway - not just cholesterol production, but pathways essential for muscle-cell energy, repair, and recovery. /2

https://twitter.com/DanielH87145164/status/2055756406134059137

2/9 The result can be muscle pain, weakness, stiffness, cramps, loss of endurance, and delayed healing.
There is also published evidence linking statins to tendon disorders, including rotator cuff injury (shoulder), Achilles tendon damage, tendonitis, and even tendon rupture. /3

1/6 If you’re the kind of person who needs a peer-reviewed, double-blind, placebo-controlled trial proving fire is hot before you’ll question pharma narratives, this probably isn’t for you.
/2 2/6 The brain is one of the most cholesterol-dense organs in the human body. Not by accident. Cholesterol is essential for neuronal membranes, synapse formation, myelin production, serotonin receptor function, and cellular signalling. In other words: basic brain function.
/3

1/12 The CoQ10 paradox:
Statins inhibit HMG-CoA reductase to lower cholesterol. but this same pathway is also responsible for endogenous CoQ10 synthesis.
CoQ10 is essential for mitochondrial energy production, especially in tissues with the highest metabolic /2 2/12 demand: skeletal muscle and the heart.
Metabolism is how cells “breathe.” Oxygen delivery is only half the equation - mitochondria require CoQ10 to transfer electrons and generate ATP. Without adequate CoQ10, cellular energy production is impaired. /3

1/9 Please don’t be fooled. Statin damage is not a “side effect.” It is the direct biological consequence of blocking the mevalonate pathway by inhibiting HMG-CoA reductase - the enzyme responsible for producing mevalonate.
/2 2/9 What is often called “statin intolerance” is evidence of toxicity. Some cells cannot compensate for the mevalonate blockade by increasing reductase activity, and the result is direct cellular damage. Pharmaceutical companies knew this decades ago.
/3

1/8 NNT (Number Needed to Treat) and NNH (Number Needed to Harm) for statins are often presented with surgical precision, as if they describe real, identifiable patients. They don’t.
/2 2/8 They are statistical artefacts built from trial design choices, group averages, and endpoint definitions - not direct clinical observations.
/3

1/15 I often hear the claim that statins can be “very helpful in secondary prevention” - meaning after a heart attack or stroke, while being far less effective in primary prevention.
But how can that logically be true ? /2

https://twitter.com/markkaplan20/status/2052627671780036971

2/15 If a drug genuinely prevents CVD, why would the mechanism suddenly become beneficial only after damage has already occurred ?
If statins truly reduced the underlying risk of CVD, we should expect to see consistent benefit across both primary and secondary prevention. /3

1/8 This 2013 post was written by an administrator of a “statin side effects” forum, sharing her husband’s experience in the hope others may avoid a similar outcome. /2 2/8 Her husband, now 68, underwent quadruple bypass surgery at age 52 after a stress test revealed a major blockage. Following surgery, he was prescribed statins and blood pressure medication. Previously very active and healthy, he was no longer able to run due to muscle pain. /3

1/10 Challenging the LDL Dogma:
The dominant narrative claims that elevated LDL directly causes atherosclerosis by accumulating in arterial walls and forming plaques. Yet if LDL were truly the primary driver, CVD would track consistently with LDL levels. It does not. /2 2/10 Contradictory clinical reality:
There are documented cases, including those discussed by Dr. Malcolm Kendrick, of individuals with familial hypercholesterolemia and extremely high LDL who show no coronary artery disease even after decades of exposure. /3

1/7 Statins are widely promoted as protective, yet they come with a clear metabolic cost. They increase the risk of new-onset diabetes by impairing pancreatic beta-cell function and reducing peripheral insulin sensitivity, contributing to insulin resistance /2 2/7 - a central driver of atherosclerosis.
The idea that statins “stabilize” plaque is misleading. A more accurate description is that they promote calcification. Rather than reducing plaque burden, they appear to shift its composition. Something often rebranded as benefit. /3

1/12 Statins: the grand illusion of modern medicine -lowering numbers on paper while masking what is happening beneath the surface.
For many doctors, prescribing statins has become a routine, low-friction response to managing cholesterol /2 2/12 - often prioritizing convenience over deeper investigation into root causes.
All statins work in essentially the same way: by inhibiting the body’s production of HMG-CoA reductase, the rate-controlling enzyme of the mevalonate pathway. /3

1/12 It is often claimed that one of the pleiotropic effects of statin drugs is their ability to act as anticoagulants. However, this “beneficial” effect may appear less favourable when examined more closely.
/2 2/12 Statins influence blood clotting through multiple mechanisms. Statins exert anticoagulant effects partly by downregulating tumour necrosis factor (TNF) expression and increasing endothelial thrombomodulin (TM) expression, which reduces thrombin generation.
/3

1/11 Despite the data, approx 50% of patients discontinue statins within 6 months and only ~20% of high-risk patients remain on them at 5 years. That’s framed as “non-adherence” or “intolerance”, but the response is not to question the drug, but to question the patient.
/2 2/11 We’re now seeing a very consistent narrative:
Lower doses. Intermittent dosing. Switch statins. “Re-challenge”. “Micro-dose until tolerated.” All under the language of “building trust”.
/3

1/11 LDL-C - the cholesterol carried in LDL particles is usually not even directly measured in routine blood tests.
It’s calculated.
For years, labs used the Friedewald equation, which has long been known to underestimate LDL-C in many people. /2 2/11 Now many labs have switched to newer formulas like the Martin-Hopkins equation, which often produce higher values from the exact same blood sample.
Same blood. Different maths. Higher result.
/3

1/12 For years I’ve looked into statins, and I’m going to be blunt: the damage they can do is being downplayed, and in some cases, outright missed.
In a clinical series from a neuro rehabilitation setting, patients didn’t come in complaining of muscle pain,the symptom /2 2/12 everyone is told to watch for. They came in because they were losing the ability to walk properly.
They were slowing down. Struggling to rise from chairs. Becoming unstable when turning. Quiet, progressive disability.
/3

1/6 I’ve studied statins for nearly 20 years, based on independent research, not pharma narratives or manipulated trials. Statins block the mevalonate pathway, which produces cholesterol and essential molecules like CoQ10, GGPP, FPP, steroid hormones, heme-A, /2

https://twitter.com/ApoDudz/status/2041555453436395984

2/6 and fat-soluble vitamins.
This blockade stresses mitochondria, destabilizes cell membranes, disrupts protein prenylation, and interferes with critical signaling pathways. Tissues with high energy demand: muscle, neurons, heart, immune cells, are particularly vulnerable. /3

1/6 The muscle pain you experience when taking statins is a red flag that your muscle cells are in serious trouble. By inhibiting the mevalonate pathway, statins up-regulate atrophy genes, cause cell apoptosis, and damage muscle fibres.
Statins also affect calcium regulation /2 2/6 inside muscle cells, particularly through changes in the Sarcoplasmic Reticulum, which controls calcium release and re-uptake. When calcium is excessive, muscles may twitch or cramp. Even more importantly, your heart muscle is also affected by excess calcium. /3

1/10 People often tell me to “look at the statin trials” sponsored by the pharmaceutical industry. Personally, I prefer to start with the mechanism of action of statins. When you do that, the scale of the claims being made begins to look implausible, which raises serious /2 2/10 questions about how those trial results were produced.
As has long been observed, individuals who are overly confident in their theories are not only less likely to make genuine discoveries, but they also tend to be poor observers. Their interpretations are shaped by /3

1/8 What the LDL is going on ? "Because the presence of coronary artery disease can be associated with the proportion of small, dense LDL, we analysed the effect of statins on small, dense LDL subfractions in people without coronary artery disease. /2 2/8 Unexpectedly, in the analysis, the proportion of small, dense LDL was significantly higher in patients treated with statins. Moreover, there were no differences in CRP, plasma fibrinogen, HOMA–IR,BMI, or metabolic syndrome between the statin and control groups. /3

1/11 If you went to a doctor with a broken leg and he started putting a cast on your arm, you’d question it immediately. Yet something similar is happening in how we approach heart disease. /2 2/11 Statins block the mevalonate pathway, a fundamental biological process involved in more than just cholesterol production. This pathway is essential for cellular energy, hormone synthesis, and repair mechanisms. /3

1/13 We live in a post-truth era where single biomarkers are taken out of context and used to construct incomplete, and often misleading, narratives. ApoB is one of the clearest examples of this. /2 2/13 Measuring ApoB in isolation is fundamentally misleading, because while it reflects the number of atherogenic particles, it tells us nothing about the protective role of ApoA1-containing lipoproteins. It is the ApoB/ApoA1 ratio that truly matters, as it captures /3